Boehringer Ingelheim – PeptideBlog

Boehringer Ingelheim

Boehringer Ingelheim

17 registered trials on this site, 2 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.

Compounds covered

Registered trials

Trial	Compound	Phase	Status	Sponsor	Enrolled	Primary completion	Registry updated
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis NCT06632457	Survodutide	Phase 3	Recruiting	Boehringer Ingelheim	1,590	Jun 5, 2029	Oct 1, 2026
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis NCT06632444	Survodutide	Phase 3	Recruiting	Boehringer Ingelheim	1,800	Dec 27, 2031	Oct 1, 2026
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver NCT05202353	Survodutide	Phase 1	Active not recruiting	Boehringer Ingelheim	29	Jan 6, 2027	Sep 9, 2026
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight NCT06066528	Survodutide	Phase 3	Completed	Boehringer Ingelheim	755	Dec 12, 2025	Aug 6, 2026
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity NCT06745284	Survodutide	Phase 1	Active not recruiting	Boehringer Ingelheim	64	Jan 8, 2027	May 12, 2026
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) NCT06309992	Survodutide	Phase 3	Completed	Boehringer Ingelheim	218	Oct 9, 2025	Apr 30, 2026
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems NCT06352411	Survodutide	Phase 1	Completed	Boehringer Ingelheim	42	Sep 16, 2025	Mar 13, 2026
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity NCT06200467	Survodutide	Phase 1	Completed	Boehringer Ingelheim	110	Oct 22, 2025	Mar 13, 2026
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight NCT06066515	Survodutide	Phase 3	Completed	Boehringer Ingelheim	726	Dec 2, 2025	Mar 12, 2026
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood NCT05896384	Survodutide	Phase 1	Completed	Boehringer Ingelheim	32	Feb 14, 2025	Apr 16, 2025
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) NCT04771273	Survodutide	Phase 2	Completed	Boehringer Ingelheim	295	Nov 9, 2023	Dec 3, 2024
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 NCT05296733	Survodutide	Phase 1	Completed	Boehringer Ingelheim	82	Dec 29, 2023	Aug 15, 2024
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight NCT04667377	Survodutide	Phase 2	Completed	Boehringer Ingelheim	387	Sep 15, 2022	Nov 2, 2023
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. NCT04153929	Survodutide	Phase 2	Completed	Boehringer Ingelheim	413	Oct 8, 2021	Nov 29, 2022
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) NCT00148486	Tesofensine	Phase 2	Completed	Boehringer Ingelheim	261	Mar 2005	Oct 29, 2013
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer’s Type NCT00153010	Tesofensine	Phase 2	Completed	Boehringer Ingelheim	430	Mar 2005	Oct 29, 2013
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations NCT00148512	Tesofensine	Phase 2	Completed	Boehringer Ingelheim	254	Feb 2005	Oct 29, 2013

Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.